🇺🇸 FDA
Patent

US 7429571

Therapeutic furopyrimidines and thienopyrimidines

granted A61KA61K31/675A61K31/7076

Quick answer

US patent 7429571 (Therapeutic furopyrimidines and thienopyrimidines) held by BioCryst Pharmaceuticals, Inc. expires Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Sep 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/675, A61K31/7076, A61K38/212, A61K38/2292